INVESTOR RELATIONS CONTACT:
Ralph Giacobbe
860-787-7968
Ralph.Giacobbe@TheCignaGroup.com
MEDIA CONTACT:
Justine Sessions
860-810-6523
Justine.Sessions@Evernorth.com
The Cigna Group Reports Strong First Quarter 2025 Results, Raises 2025 Outlook
| • |
Total revenues for the first quarter 2025 increased 14% to $65.5 billion
|
| • |
Shareholders’ net income for the first quarter 2025 was $1.3 billion, or $4.85 per share
|
| • |
Adjusted income from operations1 for the first quarter 2025 was $1.8 billion, or $6.74 per share
|
| • |
2025 adjusted income from operations1,2 increased to at least $29.60 per share2
|
BLOOMFIELD, CT, May 2, 2025 – Global health company The
Cigna Group (NYSE: CI) today reported strong first quarter 2025 results, reflecting growth and focused execution across its diversified portfolio of businesses.
“We are building a more sustainable health care model by successfully delivering on our series of commitments and actions to improve transparency
and support for our customers and patients,” said David M. Cordani, chairman and CEO of The Cigna Group. “Our strong first quarter results and increase in outlook for full-year earnings reflects the strength of our Evernorth Health Services and Cigna
Healthcare growth platforms in a dynamic environment.”
Shareholders’ net income for first quarter 2025 was $1.3 billion, or $4.85 per share, and
compares with a net loss of $0.3 billion, or $0.97 per share, for first quarter 2024.
The Cigna Group’s adjusted income from operations1 for first
quarter 2025 was $1.8 billion, or $6.74 per share, compared with $1.9 billion, or $6.47 per share, for first quarter 2024.
The Cigna Group completed the divestiture of its Medicare businesses to HCSC on March 19th, 20253.
A reconciliation of shareholders’ net income to adjusted income from operations1 is provided on the following page and on Exhibit 1 of
this earnings release.
CONSOLIDATED HIGHLIGHTS
The following table includes highlights of results and reconciliations of
total revenues to adjusted revenues4 and shareholders’ net income to adjusted income from operations1:
Consolidated Financial Results (dollars in millions):
|
|
|
Three Months Ended
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
|
2025
|
|
|
2024
|
|
|
2024
|
|
| |
|
|
|
|
|
|
|
|
|
|
Total Revenues
|
|
$
|
65,502
|
|
|
$
|
57,255
|
|
|
$
|
65,649
|
|
|
Net Investment Results from Equity Method Investments4
|
|
|
(50
|
)
|
|
|
(8
|
)
|
|
|
34
|
|
|
Adjusted Revenues4
|
|
$
|
65,452
|
|
|
$
|
57,247
|
|
|
$
|
65,683
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Earnings, net of taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders’ Net Income
|
|
$
|
1,323
|
|
|
$
|
(277
|
)
|
|
$
|
1,424
|
|
|
Net Investment (Gains) Losses1
|
|
|
(48
|
)
|
|
|
1,827
|
|
|
|
(18
|
)
|
|
Amortization of Acquired Intangible Assets1
|
|
|
336
|
|
|
|
322
|
|
|
|
375
|
|
|
Special Items1
|
|
|
229
|
|
|
|
3
|
|
|
|
64
|
|
|
Adjusted Income from Operations1
|
|
$
|
1,840
|
|
|
$
|
1,875
|
|
|
$
|
1,845
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders’ Net Income, per share
|
|
$
|
4.85
|
|
|
$
|
(0.97
|
)
|
|
$
|
5.13
|
|
|
Adjusted Income from Operations1, per share
|
|
$
|
6.74
|
|
|
$
|
6.47
|
|
|
$
|
6.64
|
|
| • |
Total revenues for first quarter 2025
increased 14% relative to first quarter 2024, reflecting growth of existing client relationships and strong specialty pharmacy growth in Evernorth Health Services.
|
| • |
The SG&A expense ratio5 and adjusted SG&A expense ratio5 were 6.4% and 5.8%, respectively, for first quarter 2025, compared to 6.5% and 6.4%, respectively, in first quarter 2024, reflecting
strong revenue growth and business mix shift.
|
| • |
Year to date through May 1, 2025, the company repurchased 8.2 million shares of common stock for approximately $2.6 billion.
|
CUSTOMER RELATIONSHIPS
The following table summarizes The Cigna Group’s medical customers and overall customer relationships:
Customer Relationships (in thousands):
| |
|
As of the Periods Ended
|
|
| |
|
March 31,
|
|
|
December 31,
|
|
| |
|
2025
|
|
|
2024
|
|
|
2024
|
|
| |
|
|
|
|
|
|
|
|
|
|
Total Pharmacy Customers6
|
|
|
122,283
|
|
|
|
122,767
|
|
|
|
118,304
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Healthcare
|
|
|
16,364
|
|
|
|
17,562
|
|
|
|
17,502
|
|
|
International Health
|
|
|
1,679
|
|
|
|
1,622
|
|
|
|
1,645
|
|
|
Total Medical Customers6
|
|
|
18,043
|
|
|
|
19,184
|
|
|
|
19,147
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Behavioral Care
|
|
|
23,416
|
|
|
|
23,801
|
|
|
|
23,932
|
|
|
Dental
|
|
|
18,466
|
|
|
|
18,443
|
|
|
|
18,258
|
|
|
Medicare Part D
|
|
|
—
|
|
|
|
2,558
|
|
|
|
2,571
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Customer Relationships6
|
|
|
182,208
|
|
|
|
186,753
|
|
|
|
182,212
|
|
| • |
Total customer relationships6 at March 31, 2025 were 182.2 million. Excluding the impact of the HCSC transaction3, total customer relationships6 increased 1% from December
31, 2024.
|
| • |
Total pharmacy customers6 at March 31, 2025 increased 3% from December 31, 2024 to 122.3 million due to new
sales and the continued expansion of relationships.
|
| • |
Total medical customers6 at March 31, 2025 decreased 6% from December 31, 2024 to 18.0 million, primarily reflecting the impact of the HCSC transaction3. Excluding the impact of the HCSC transaction3, total medical customers6
as of March 31, 2025 were consistent relative to December 31, 2024.
|
HIGHLIGHTS OF SEGMENT RESULTS
See Exhibit 1 for a reconciliation of adjusted income from operations1 to shareholders’ net income.
Evernorth Health Services
This segment includes the Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide
independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live richer, healthier lives.
Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services such as drug claim
adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of
complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services.
Financial Results (dollars in millions):
|
|
|
Three Months Ended
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
|
2025
|
|
|
2024
|
|
|
2024
|
|
|
Total Adjusted Revenues
|
|
|
|
|
|
|
|
|
|
|
Pharmacy Benefit Services
|
|
$
|
29,742
|
|
|
$
|
26,107
|
|
|
$
|
30,273
|
|
|
Specialty and Care Services
|
|
$
|
23,939
|
|
|
$
|
20,119
|
|
|
$
|
23,471
|
|
|
Adjusted Revenues4
|
|
$
|
53,681
|
|
|
$
|
46,226
|
|
|
$
|
53,744
|
|
|
Adjusted Income from Operations, Pre-Tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmacy Benefit Services
|
|
$
|
544
|
|
|
$
|
525
|
|
|
$
|
1,198
|
|
|
Specialty and Care Services
|
|
$
|
890
|
|
|
$
|
835
|
|
|
$
|
948
|
|
|
Adjusted Income from Operations, Pre-Tax1
|
|
$
|
1,434
|
|
|
$
|
1,360
|
|
|
$
|
2,146
|
|
|
Margin, Pre-Tax7
|
|
|
2.7
|
%
|
|
|
2.9
|
%
|
|
|
4.0
|
%
|
| • |
Evernorth Health Services first quarter 2025 adjusted revenues4 and adjusted income from operations, pre-tax1, increased 16% and 5%, respectively, relative to first quarter 2024.
|
| • |
For Pharmacy Benefit Services first quarter 2025 relative to first quarter 2024:
|
|
◦ |
Adjusted revenues4 increased 14% reflecting growth of existing client relationships and new
business.
|
|
◦ |
Adjusted income from operations, pre-tax1, increased 4% reflecting continued affordability
improvements, partially offset by strategic investments to support business growth.
|
| • |
For Specialty and Care Services first quarter 2025 relative to first quarter 2024:
|
|
◦ |
Adjusted revenues4 increased 19% reflecting strong specialty volume growth.
|
|
◦ |
Adjusted income from operations, pre-tax1, increased 7% reflecting strong organic growth in
specialty businesses, including increased Humira biosimilar adoption, partially offset by strategic investments to support business growth. Year-over-year growth was also
impacted by lower net investment income in first quarter 2025 compared to first quarter 2024.
|
Cigna Healthcare
This segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and
coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients and individual health insurance plans. International Health provides health care solutions in
our international markets, as well as health solutions for globally mobile individuals and employees of multinational organizations. U.S. Healthcare included the Medicare and related businesses until the divestiture of such businesses to Health Care
Services Corporation (“HCSC”)3 on March 19, 2025.
Financial Results (dollars in millions):
|
|
|
Three Months Ended
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
|
2025
|
|
|
2024
|
|
|
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Revenues4,8
|
|
$
|
14,482
|
|
|
$
|
13,277
|
|
|
$
|
13,331
|
|
|
Adjusted Income from Operations, Pre-Tax1
|
|
$
|
1,287
|
|
|
$
|
1,340
|
|
|
$
|
511
|
|
|
Margin, Pre-Tax7
|
|
|
8.9
|
%
|
|
|
10.1
|
%
|
|
|
3.8
|
%
|
| • |
First quarter 2025 adjusted revenues4,8 increased 9% relative
to first quarter 2024, primarily reflecting premium rate increases to cover expected
increases in underlying medical costs.
|
| • |
First quarter 2025 adjusted income from operations, pre-tax1, decreased 4% relative to first
quarter 2024, primarily driven by a higher MCR5, partially offset by a lower SG&A expense ratio5.
|
| • |
The Cigna Healthcare MCR5 was 82.2% for first quarter 2025 compared to 79.9% for first quarter 2024.
The increase for the first quarter was primarily driven by expected higher stop loss medical costs. The HCSC transaction3
closed later than the company’s financial planning assumptions, increasing the first quarter Cigna Healthcare MCR5 as the
Medicare businesses operate at a higher MCR5 compared to the rest of the portfolio.
|
| • |
Cigna Healthcare net medical costs payable9 was $4.37 billion at March 31, 2025
which decreased relative to $4.86 billion at December 31, 2024, and $5.66 billion at March 31, 2024, driven by the HCSC transaction3.
Favorable prior year reserve development on a gross pre-tax basis was $222 million and $226
million for the three months ended March 31, 2025 and 2024, respectively.
|
Corporate and Other Operations
Corporate reflects interest expense, amounts not allocated to operating segments and includes intersegment eliminations. Other
Operations is comprised of Corporate Owned Life Insurance (“COLI”), the Company’s run-off operations and other non-strategic businesses.
Financial Results (dollars in millions):
|
|
|
Three Months Ended
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
|
2025
|
|
|
2024
|
|
|
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted (Loss) from Operations, Pre-Tax1
|
|
$
|
(411
|
)
|
|
$
|
(391
|
)
|
|
$
|
(424
|
)
|
2025
OUTLOOK2
The Cigna Group’s outlook2 for full year 2025 consolidated adjusted income from
operations1,2 is $29.60 per share2. Additionally, this outlook includes the impact of expected future share repurchases and anticipated 2025 dividends.
(dollars in millions, except where noted and per share amounts)
|
2025 Consolidated Metrics
|
Projection for Full Year Ending
December 31, 2025
|
|
Change from
Prior Projection
|
|
|
Adjusted Income from Operations, per share1,2
|
at least $29.60
|
|
+$0.10
|
|
|
Evernorth Adjusted Income from Operations, Pre-Tax1,2
|
at least $7,200
|
|
|
|
|
Cigna Healthcare Adjusted Income from Operations, Pre-Tax1,2
|
at least $4,125
|
|
+$25
|
|
|
Cigna Healthcare Medical Care Ratio2,5
|
83.2% to 84.2%
|
|
|
|
The foregoing statements represent the Company’s current estimates of The Cigna Group’s 2025 consolidated and segment adjusted income from operations1,2 and other key metrics as of the date of this release. Actual results may differ materially depending on a number of factors.
Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates.
This quarterly earnings release and the Quarterly Financial Supplement are available on The Cigna Group’s website in the Investor Relations section
(https://investors.thecignagroup.com/overview/default.aspx). Management will be hosting a conference call to review first
quarter 2025 results and discuss full year 2025 outlook beginning today at 8:30 a.m. ET. A
link to the conference call is available in the Investor Relations section of The Cigna Group’s website located at https://investors.thecignagroup.com/events-and-presentations/default.aspx.
The call-in numbers for the conference call are as follows:
Live Call
| |
(888) 566-1889
|
(Domestic)
|
| |
(773) 799-3989
|
(International)
|
Passcode: 05022025
Replay
| |
(800) 835-8067
|
(Domestic)
|
| |
(203) 369-3354
|
(International)
|
It is strongly suggested you dial in to the conference call by 8:15 a.m. ET.
About The Cigna Group
The Cigna Group (NYSE: CI) is a global health company committed
to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under
Evernorth Health Services, Cigna Healthcare, or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 markets and jurisdictions, and has more than 180 million customer relationships around the world. Learn more at thecignagroup.com.
Notes:
|
1. |
Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group’s management because it
presents the underlying results of operations of the Company’s businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders’ net income (loss). Adjusted income (loss) from operations is defined as
shareholders’ net income (loss) (or income (loss) before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible
assets and special items. The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management
believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results.
Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income (loss). See Exhibit 1 for a
reconciliation of consolidated adjusted income from operations to shareholders’ net income (loss).
|
|
2. |
Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income (loss), on a forward-looking basis because it
is unable to predict, without unreasonable effort, certain components thereof including (i) future net investment results and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are
beyond The Cigna Group’s control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially.
|
The Company’s outlook excludes the potential effects of any other business combinations that may occur after
the date of this earnings release. The Company’s outlook includes the potential effects of expected future share repurchases and anticipated 2025 dividends.
The timing and actual number of shares repurchased will depend on a variety of factors, including price,
general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through
Rule 10b5-1 trading plans, or privately negotiated transactions. The program may be suspended or discontinued at any time.
|
3. |
On March 19, 2025, the company completed the sale (the “HCSC transaction”) of its Medicare Advantage, Medicare Individual Stand-Alone
Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Services Corporation (“HCSC”).
|
|
4. |
Adjusted revenues is used by The Cigna Group’s management because it facilitates analysis of trends in underlying revenue. The Company defines adjusted
revenues as total revenues excluding the following adjustments: special items and The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.
Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of
past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See Exhibit 1 for a
reconciliation of consolidated adjusted revenues to total revenues.
|
|
5. |
Operating ratios are defined as follows:
|
|
• |
The Cigna Healthcare medical care ratio (“MCR”) represents medical costs as a percentage of premiums for all Cigna Healthcare risk products provided through
guaranteed cost or experience-rated funding arrangements. Changes in percentages may be expressed in basis points (“bps”).
|
|
• |
SG&A expense ratio on a GAAP basis for the first quarter 2025 represents
enterprise selling, general and administrative expenses of $4,213 million as a percentage of total revenue of $65.5 billion at a consolidated level. SG&A expense ratio on a GAAP basis for the first quarter 2024 represents enterprise selling, general
and administrative expenses of $3,705 million as a percentage of total revenue of $57.3 billion
at a consolidated level.
|
|
• |
Adjusted SG&A expense ratio for the first quarter 2025 represents enterprise
selling, general and administrative expenses of $3,799 million excluding special items of $414
million as a percentage of adjusted revenue at a consolidated level. Adjusted SG&A expense ratio for the first quarter 2024 represents enterprise selling, general
and administrative expenses of $3,668 million excluding special items of $37 million as a
percentage of adjusted revenue at a consolidated level.
|
|
6. |
Customer relationships are defined as
follows:
|
|
• |
Total medical customers includes individuals who meet any one of the following criteria: are covered under a medical insurance policy,
managed care arrangement, or administrative services agreement issued by Cigna Healthcare; have access to Cigna Healthcare’s provider network for covered services under their medical plan; or have medical claims that are administered by Cigna
Healthcare.
|
|
• |
Total customer relationships and total medical customers as of December 31, 2024, excluding the impact of the HCSC transaction3,
were 179,712 thousand and 18,055 thousand, respectively.
|
|
7. |
Margin, pre-tax, is calculated by dividing adjusted income (loss) from operations, pre-tax by adjusted revenues for each segment.
|
|
8. |
The Cigna Group owns noncontrolling interests in certain operating joint ventures. As such, the adjusted revenues for the Cigna Healthcare segment only include
the Company’s share of the joint ventures’ earnings reported in Fees and Other Revenues using the equity method of accounting under GAAP.
|
|
9. |
Medical costs payable within the Cigna Healthcare segment are presented net of
reinsurance and other recoverables. The gross medical costs payable balance was $4.51 billion as of March
31, 2025, $5.02 billion as of December 31, 2024, and $5.86 billion as of March 31, 2024.
|
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group’s current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking
statements may include, among others, statements concerning our projected outlook for 2025 (including adjusted revenues; adjusted income from operations, including on a per share, and segment basis; adjusted SG&A expense ratio; adjusted effective
tax rate; cash flow from operations; capital expenditures; shareholder dividends; weight average shares outstanding; medical care ratio; and total medical customers); future financial or operating performance, including our ability to improve the
health and vitality of those we serve; future growth, business strategy and strategic or operational initiatives, including our ability to successfully implement actions across our business to strengthen our platform and build a more sustainable
model for healthcare; economic, regulatory or competitive environments; capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; and other statements regarding The Cigna Group’s future
beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as “believe,” “expect,” “project,” “plan,” “intend,” “anticipate,” “estimate,”
“predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.
Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from
those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly
changing industry; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition, inflation and other pressures that could compress our margins or
result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory
relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts
provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems; our
ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning; political, legal, operational, regulatory, economic and other risks
that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or
underperformance relative to expectations which could lead to an impairment charge; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; potential
liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; the substantial level of government regulation over our business and the potential effects of new laws or
regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate in government-sponsored programs; the outcome of litigation, regulatory
audits and investigations; compliance with applicable privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions, the risk of a recession
or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and
the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available
through the Investor Relations section of www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to
risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as
may be required by law.
| THE CIGNA GROUP |
|
|
|
|
Exhibit 1
|
|
| COMPARATIVE SUMMARY OF FINANCIAL RESULTS (unaudited) |
|
|
|
|
|
|
| |
|
Three Months Ended
|
|
|
Three Months Ended
|
|
| |
|
March 31,
|
|
|
December 31,
|
|
|
(Dollars in millions, except per share amounts)
|
|
2025
|
|
|
2024
|
|
|
2024
|
|
| |
|
|
|
|
|
|
|
|
|
|
REVENUES
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
Pharmacy revenues
|
|
$
|
48,633
|
|
|
$
|
42,036
|
|
|
$
|
49,941
|
|
|
Premiums
|
|
|
12,736
|
|
|
|
11,603
|
|
|
|
11,503
|
|
|
Fees and other revenues
|
|
|
3,895
|
|
|
|
3,326
|
|
|
|
3,928
|
|
|
Net investment income
|
|
|
238
|
|
|
|
290
|
|
|
|
277
|
|
|
Total revenues
|
|
|
65,502
|
|
|
|
57,255
|
|
|
|
65,649
|
|
|
Net investment results from certain equity method investments
|
|
|
(50
|
)
|
|
|
(8
|
)
|
|
|
34
|
|
|
Adjusted revenues (1)
|
|
$
|
65,452
|
|
|
$
|
57,247
|
|
|
$
|
65,683
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders’ net income (loss)
|
|
$
|
1,323
|
|
|
$
|
(277
|
)
|
|
$
|
1,424
|
|
|
Pre-tax adjusted income (loss) from operations by segment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Evernorth Health Services
|
|
$
|
1,434
|
|
|
$
|
1,360
|
|
|
$
|
2,146
|
|
|
Cigna Healthcare
|
|
|
1,287
|
|
|
|
1,340
|
|
|
|
511
|
|
|
Corporate and Other Operations
|
|
|
(411
|
)
|
|
|
(391
|
)
|
|
|
(424
|
) |
|
Adjusted income tax expense
|
|
|
(470
|
)
|
|
|
(434
|
)
|
|
|
(388
|
) |
|
Consolidated after-tax adjusted income from operations
|
|
$
|
1,840
|
|
|
$
|
1,875
|
|
|
$
|
1,845
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares (in thousands) (2)
|
|
|
272,953
|
|
|
|
289,717
|
|
|
|
277,784
|
|
|
Common shares outstanding (in thousands)
|
|
|
269,773
|
|
|
|
284,014
|
|
|
|
273,789
|
|
|
SHAREHOLDERS’ EQUITY at March 31,
|
|
$
|
40,226
|
|
|
$
|
41,181
|
|
|
|
|
|
|
SHAREHOLDERS’ EQUITY PER SHARE at March 31,
|
|
$
|
149.11
|
|
|
$
|
145.00
|
|
|
|
|
|
| |
|
Three Months Ended
|
|
|
Three Months Ended
|
|
| |
|
March 31,
|
|
|
December 31,
|
|
| |
|
2025
|
|
|
2024
|
|
|
2024
|
|
|
(Dollars in millions, except per share amounts)
|
|
Pre-tax
|
|
|
After-
tax
|
|
|
Pre-tax
|
|
|
After-
tax
|
|
|
Pre-tax
|
|
|
After-
tax
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SHAREHOLDERS’ NET INCOME (LOSS)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders’ net income (loss)
|
|
|
|
|
$
|
1,323
|
|
|
|
|
|
$
|
(277
|
)
|
|
|
|
|
$
|
1,424
|
|
|
Adjustments to reconcile adjusted income from operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net investment (gains) losses (3)
|
|
$
|
(48
|
)
|
|
|
(48
|
)
|
|
$
|
1,828
|
|
|
|
1,827
|
|
|
$
|
(34
|
)
|
|
|
(18
|
)
|
|
Amortization of acquired intangible assets
|
|
|
422
|
|
|
|
336
|
|
|
|
423
|
|
|
|
322
|
|
|
|
424
|
|
|
|
375
|
|
|
Special Items
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Integration and transaction-related costs
|
|
|
216
|
|
|
|
164
|
|
|
|
37
|
|
|
|
29
|
|
|
|
98
|
|
|
|
76
|
|
|
Strategic optimization program
|
|
|
215
|
|
|
|
163
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
Deferred tax expenses, net
|
|
|
—
|
|
|
|
17
|
|
|
|
—
|
|
|
|
17
|
|
|
|
—
|
|
|
|
9
|
|
|
(Gain) loss on sale of businesses
|
|
|
(41
|
)
|
|
|
(115
|
)
|
|
|
19
|
|
|
|
(43
|
)
|
|
|
(130
|
)
|
|
|
(21
|
)
|
|
Adjusted income from operations (4)
|
|
|
|
|
|
$
|
1,840
|
|
|
|
|
|
|
$
|
1,875
|
|
|
|
|
|
|
$
|
1,845
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DILUTED EARNINGS PER SHARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders’ net income (loss) (5)
|
|
|
|
|
|
$
|
4.85
|
|
|
|
|
|
|
$
|
(0.97
|
)
|
|
|
|
|
|
$
|
5.13
|
|
|
Adjustments to reconcile to adjusted income from operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net investment (gains) losses (3)
|
|
$
|
(0.18
|
)
|
|
|
(0.18
|
)
|
|
$
|
6.31
|
|
|
|
6.31
|
|
|
$
|
(0.12
|
)
|
|
|
(0.06
|
)
|
|
Amortization of acquired intangible assets
|
|
|
1.54
|
|
|
|
1.23
|
|
|
|
1.46
|
|
|
|
1.10
|
|
|
|
1.53
|
|
|
|
1.34
|
|
|
Special Items
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Integration and transaction-related costs
|
|
|
0.79
|
|
|
|
0.60
|
|
|
|
0.12
|
|
|
|
0.10
|
|
|
|
0.35
|
|
|
|
0.27
|
|
|
Strategic optimization program
|
|
|
0.79
|
|
|
|
0.60
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
Deferred tax expenses, net
|
|
|
—
|
|
|
|
0.06
|
|
|
|
—
|
|
|
|
0.06
|
|
|
|
—
|
|
|
|
0.03
|
|
|
(Gain) loss on sale of businesses
|
|
|
(0.15
|
)
|
|
|
(0.42
|
)
|
|
|
0.07
|
|
|
|
(0.15
|
)
|
|
|
(0.47
|
)
|
|
|
(0.07
|
)
|
|
Adjusted income from operations (2) (4)
|
|
|
|
|
|
$
|
6.74
|
|
|
|
|
|
|
$
|
6.47
|
|
|
|
|
|
|
$
|
6.64
|
|
(1) Adjusted revenues is defined as total revenues excluding the following adjustments: special items and The Cigna Group’s
share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. These items are excluded because they are not indicative of past or future underlying performance of our
businesses.
(2) The calculation of weighted average shares includes the impact of potentially dilutive securities for the calculation of
Adjusted income from operations per share.
(3) Includes Net investment gains/losses as presented in our
Consolidated Statements of Income, as well as the Company’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues
in our Consolidated Statements of Income.
(4) Adjusted income (loss) from operations is defined as
shareholders’ net income (loss) (or income (loss) before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding the following adjustments: net investment gains/losses, amortization of
acquired intangible assets and special items. The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded.
(5) For the three months ended March 31, 2024, due to the anti-dilutive effect resulting from the Shareholders’ net loss for the
period, the impact of potentially dilutive securities has been excluded from the calculation of weighted average shares for the calculation of diluted Shareholders’ net loss per share. Weighted average shares used to calculate diluted Shareholders’
net loss per share for the three months ended March 31, 2024 were 286,465 thousand. For the three months ended March 31, 2025 and December 31, 2024, the calculation of weighted average shares includes the impact of potentially dilutive securities for the calculation of diluted Shareholders net income per share.
